We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cenkos have issued an update with this BUT with nothing else of any worth.
Nice Mr Langton.
LPLDL is looking more compelling. I'm hearing inquiries are coming in.
https://lemminginvestor.substack.com/p/optibiotix-health-plc-d98?r=kcv2o&utm_campaign=post&utm_medium=web
LPLDL study now on Roehampton website as of today 1 Feb 2022
https://www.roehampton.ac.uk/life-and-health-sciences/news/probiotic-study-shows-statistically-significant-reductions-in-bad-cholesterol/
Cardiovascular disease remains the world’s number one killer, with most people at risk prescribed statins and aspirin. This research is therefore a significant step forward for a probiotic that can truly make a difference.
Dr Adele Costabile, lead researcher on the study and Reader of Nutrition in our School of Health and Life Sciences added “it is a very promising study in the fight against cardiovascular disease with the probiotic Lactobacillus plantarum LPLDL.”
This research is part of an ongoing research project funded by OptiBiotix Health Plc.
mol
Hi AquaeSulis01
Not sure if this has been posted before
but a review of seed health's Daily Synbiotic
https://muscleandbrawn.com/reviews/seed-probiotic-review/
mol
and summary now on website
https://optibiotix.com/lpldl-from-probiotix-health-showcases-statistically-significant-reductions-in-multiple-coronary-heart-disease-biomarkers-in-hypercholesterolemic-adults/
Extract
Stephen O’Hara, CEO at OptiBiotix, commented: “The results of this study are remarkable and firmly establish LPLDL® as the probiotic for heart health. Our previous human intervention studies have highlighted LPLDL® as an excellent candidate to reduce cholesterol across different patient groups and countries. Now, with the statistically significant results of our latest study, both partners and consumers can rest assured they are using a science-backed probiotic that not only reduces total cholesterol, but multiple risk factors associated with CHD.
“For the industry, this is a significant step forward for a probiotic that can truly make a difference, demonstrating that LPLDL® champions scientific evidence to deliver impressive results.”
mol
Published Article here
https://www.sciencedirect.com/science/article/pii/S1756464622000093
mol
https://lemminginvestor.substack.com/p/optibiotix-health-plc-edf
Thanks mol hadn't realised that was still running
https://www.optibiotix-ir.com/content/news/archive/2018/04-09-18
Think he is referring to the above rns
mol
Are you talking about Seed Health elric, if so their DS01 product contains not just LPLDL but also all these other ingredients so as a clinical trial is probably irrelevant to LPLDL?
Digestive Health / Gut Immunity / Gut Barrier Integrity Probiotic Blend
37.0 Billion AFU
Bifidobacterium longum SD-BB536-JP
Bifidobacterium breve SD-BR3-IT
Lactiplantibacillus plantarum SD-LP1-IT
Lacticaseibacillus rhamnosus SD-LR6-IT
Lacticaseibacillus rhamnosus HRVD113-US
Bifidobacterium infantis SD-M63-JP
Bifidobacterium lactis SD-BS5-IT
Bifidobacterium lactis HRVD524-US
Lactobacillus crispatus SD-LCR01-IT
Lacticaseibacillus casei HRVD300-US
Bifidobacterium breve HRVD521-US
Bifidobacterium longum HRVD90b-US
Bifidobacterium lactis SD150-BE
Limosilactobacillus fermentum SD-LF8-IT
Lacticaseibacillus rhamnosus SD-GG-BE
Limosilactobacillus reuteri RD830-FR
The real benefit from the study was outlined in the 5th Aug 2021 RNS:
" The publication of a placebo-controlled human study which shows that LPLDL® can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, with no reported side effects. This has been with the editorial board of a peer reviewed journal for a number of months. COVID publications are currently being prioritised by editors but we expect this to be published in H2. Publications on how a product works, its safety and efficacy, are important to pharmaceutical partners who may wish to sell LPLDL® as a drug, or Over the Counter (OTC) in high value hospital, GP, and pharmacy channels."
Yeah definitely. As I understand it the Seed Health one is a clinical trial.
LP-LDL may not be a drug yet. This must be the end goal, hence why one US pharma is investing up to $50 million in its attempt.
The third study has several key markers that will interest to big pharma.
It sounds like a half way house. If they'd already passed the saftey and eficacy end points required for clinical trials in the past why run more? Certainly the results demonstrate the route should be pursued and whatever hoops need to be jumped through to go for regulatory approval would be worth doing.
Skid, we need to stick to the facts indeed. LPLDL is not a new product, and it is not a drug (it is a food supplement), so it would not be subject to a multi phase clinical trial as you suggest. It has already passed all the requisite safetly, tolerability and efficacy trials that would be typical of a phase 1 and 2 study some years ago. So yes, these results can be regarded as a proper clinical trial. The company has also indicated from previous releases that it is also exploring moving LPLDL along the pharmaceutical route in addition to over the counter.
Ski, from the March Commercial and Strategic Update the study is considered the equivalent to a stage II pharma study
"LPLDL® drug biotherapeutic: The Company has employed Christopher Nother on a part time consultancy basis to explore the use of LPLDL® in pharma, either as an 'over the counter' (OTC) product, or a drug biotherapeutic in markets outside the USA. LPLDL® has already received an investigational New Drug Approval with Seed Health for a Phase II pharma clinical study. The Company will shortly be publishing placebo controlled human studies which show LPLDL® can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, without any side effects. Early discussions suggest that ProBiotix's existing humans studies provide safety, tolerance, and efficacy comparable to that typically seen in a Phase II pharma study. If this is confirmed the risk, timeline, and costs to develop LPLDL® as a drug biotherapeutic is substantially reduced. Chris is currently assessing the costs and timelines to develop LPLDL® as a drug biotherapeutic and the potential to create a biotherapeutic drug division or separate Limited company to fully exploit the opportunity and potential for significant upside."
Larus, I'm a fan here but we need to stick to facts.
This is not a medical trial in the sense most people would see it similar to a multi million £ drug test through various phases of development.
I'm not in the industry so don't know how the medical "establishment" view these studies, and then what the next step is to get these either prescribed or bought - any thoughts from investors better qualified than myself (basically all of you) very welcome.
I don't have much in this company Larus so not paying much attention. Was a genuine question. It's just a lot more song and dance is made about medical trials. Lots more information at the least.
basscadet, the study was a nine-week follow-up, single centre, double-blind, randomised, placebo controlled human intervention study. Not sure what you're expecting a proper medical trial to look like
No-one from the company is saying ditch the statins, but there is a large number of people with high cholesterol who are unable or unwilling to take statins long term for which LPLDL would be an ideal alternative
https://scopeblog.stanford.edu/2019/02/14/failure-to-take-statins-leads-to-higher-mortality/
"A lot of patients with arteries clogged by cholesterol aren’t taking their statins, Stanford researchers have found. That boosts their risk of death, according to a new study.
More than a third of patients with cardiovascular disease who have been prescribed statins to reduce cholesterol failed to take them daily, according to a review of Veterans Affairs medical records. Women and non-whites were least likely to take their prescriptions, as were the oldest and youngest patients."
Must admit I'm a little confused. These aren't proper medical trials are they? Even if they were there would then need to be regulator approval. Once that's achieved then yeah, ditch the statins.
Getting the message out there
https://www.proactiveinvestors.co.uk/companies/news/971417/optibiotix-health-says-latest-study-supports-case-for-lpldl-as-an-alternative-to-statins-971417.html
Great RNS and hopefully Hammond will open the doors so it can be sold through NHS. SP is a bargain at this price, looking for end of year results as well.
The presentation is here: https://www.youtube.com/watch?v=j5WW9Geo0rg&t=1863s